Evidence map›Paper›PMID 39544462›Full record

ArticleQuantitative imaging in medicine and surgery2024

Metastatic bone lesion type in gastric cancer patients: imaging findings of case reports.

Marta Porta-Vilaró, Juan Carlos Soler-Perromat, Ana-Belen Larque, Álvaro Bartolomé-Solanas, Jaime Isern-Kebschull, Ana-Isabel García-Diez, Montserrat Del Amo, David Fuster, Dulce Momblan, Jose Ignacio Elizalde and 2 more

Abstract readCase Reports
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marta Porta-Vilaró *Department of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.ORCID https://orcid.org/0000-0002-7462-5586
Juan Carlos Soler-Perromat *Department of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Ana-Belen LarqueDepartment of Pathology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Álvaro Bartolomé-SolanasDepartment of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Jaime Isern-KebschullDepartment of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Ana-Isabel García-DiezDepartment of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Montserrat Del AmoDepartment of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
David FusterDepartment of Nuclear Medicine, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Dulce MomblanDepartment of Gastrointestinal Surgery, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Jose Ignacio ElizaldeDepartment of Gastroenterology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Tamara SauriDepartment of Oncology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Xavier TomásDepartment of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer (GC) is the fifth most common cancer globally and the third leading cause of cancer-related deaths. While it predominantly metastasizes to the liver, peritoneum, and lungs, bone metastasis (BM) is a rare but severe complication. BM occurs in 1-20% of GC cases and is associated with a poor prognosis. Typically, BM in GC presents at advanced stages, often with non-specific symptoms, making early detection challenging. Case Description: This retrospective study analyzed 118 GC patients treated at our institution from 2010 to 2020. Among them, eight patients (6.8%) developed BM, with an equal split between osteoblastic and osteolytic types. Osteoblastic BM was observed exclusively in men, with a mean age of 72.25 years. The median time from GC diagnosis to BM onset was 27.5 months. BM was primarily detected through periodic thoracoabdominal CT scans, and bone scintigraphy confirmed the osteoblastic nature of the lesions. All patients had advanced GC and were under palliative care at the time of BM diagnosis. The average survival time from BM diagnosis was 8.5 months. Conclusions: BM in GC patients is rare but significantly worsens the prognosis. The findings suggest that osteoblastic BM may be more common in GC than previously reported, potentially due to improved imaging techniques and extended patient survival. This study underscores the importance of vigilant radiological monitoring in GC patients, particularly those with non-specific symptoms suggestive of BM. Enhanced collaboration between oncology and palliative care teams is essential to manage symptoms effectively and improve patient quality of life. Future research should focus on the incidence and management of BM in GC, particularly the role of targeted therapies in improving patient quality of life. Keywords: Bone metastasis (BM); gastric cancer (GC); osteoblastic; disease progression; case report.

Identifiers

PMID39544462
PMCPMC11558497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.